BRUSSELS, BELGIUM and MECHELEN, BELGIUM--(Marketwired - April 30, 2013) - Today NYSE Liffe,
the Europe-based derivatives business of NYSE Euronext (NYX), added
options on the shares
of Galapagos (Euronext: GLPG), a clinical stage biotech company
developing novel medicines, to its highly successful range of equity
classes. The options are available on the Brussels derivatives market of
Liffe under the ticker GLS.
Vincent Van Dessel, CEO of NYSE Euronext Brussels commented: "We are
announce the listing of options on Galapagos, a successful Belgian company
great example of our leading role in the biotech industry niche. This
will further enhance the visibility of the company."
Ade Cordell, Executive Director, Head of Equity Derivatives added:
delighted with the listing of this new option class on our Brussels
With the addition of the Galapagos option class to our existing central
book contracts, we are offering our market participants a highly
of liquid derivatives for their investment needs.
Onno van de Stolpe, CEO of Galapagos, commented: "Listing of ordinary
NYSE Euronext has played an important role in the growth of Galapagos
IPO in 2005. The listing of options on the shares of our company
further step in the company's development. We believe that this may
shareholders an alternative financial instrument on the NYSE Liffe
enhance the liquidity of our share, and increase the visibility of
the financial markets."
These American-style options will expire on the third Friday of the expiry
and will have initial lifetimes of one to twelve months. Options on
are introduced under trading symbol GLS.
Each option represents 100 shares in Galapagos and will be centrally
LCH.Clearnet SA. Liquidity in the options will be supported by All
International B.V.. NYSE Liffe lists stock options (also known as
equity options) on more than 200 leading European companies via the
Brussels, London and Paris central order books.
The introduction of the new option class on Galapagos is the second one
Belgian biotech company. Galapagos is specialized in novel
medicines, with a large pipeline of four clinical, seven
pre-clinical, and 30
discovery small-molecule and antibody programs in cystic fibrosis,
antibiotics, metabolic disease, and other indications. The Galapagos
including fee-for-service companies BioFocus, Argenta and Fidelta, has
800 employees and operates facilities in five countries, with
headquarters in Mechelen, Belgium.
To mark today's special occasion, Onno van de Stolpe, CEO of Galapagos,
opening bell which denotes the opening of NYSE Euronext's European
together with Vincent Van Dessel, CEO of NYSE Euronext Brussels.
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial
provider of innovative trading technologies. The company's exchanges in
and the United States trade equities, futures, options,
exchange-traded products. With approximately 8,000 listed issues
European Structured Products), NYSE Euronext's equities markets - the New
Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE
represent one-third of the world's equities trading, the most liquidity
global exchange group. NYSE Euronext also operates NYSE Liffe, one
leading European derivatives businesses and the world's
derivatives business by value of trading. The company offers
commercial technology, connectivity and market data products and
through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For
information, please visit: http://www.nyx.com.
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is specialized in
with a large pipeline of four clinical, seven pre-clinical, and 30
small-molecule and antibody programs in cystic fibrosis,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
of rheumatoid arthritis and potentially other inflammatory diseases,
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide
agreement whereby AbbVie will be responsible for further
commercialization after Phase 2b. Galapagos has another selective
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly
in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974
first inhibitor of FFA2 to be evaluated clinically for the treatment of
this program is currently in a Proof of Concept Phase 2 study, with
expected early 2014.
The Galapagos Group, including fee-for-service companies BioFocus,
Fidelta, has around 800 employees and operates facilities in five
with global headquarters in Mechelen, Belgium. Further information
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such
forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
NYSE Liffe lists Equity Options on Galapagos:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE